方法对比
并排查看您选择的方法；存在差异的行会高亮显示。
| Cochrane偏倚风险工具2.0用于随机对照试验× | CONSORT核查表：随机对照试验报告标准× | |
|---|---|---|
| 领域 | 研究方法论 | 研究方法论 |
| 方法族 | Process / pipeline | Process / pipeline |
| 起源年份≠ | 2019 | 2010 (original 1996) |
| 提出者≠ | Jonathan Sterne, Julian Higgins (Cochrane Collaboration) | Schulz et al. (CONSORT Group) |
| 类型≠ | Clinician-rated / Research team assessment | Trial author reporting checklist |
| 开创性文献≠ | Sterne, J. A., Savović, J., Page, M. J., Elbers, R. G., Blencowe, N. S., Boutron, I., ... & Higgins, J. P. (2019). RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ, 366, l4898. DOI ↗ | Schulz, K. F., Altman, D. G., & Moher, D. (2010). CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. The Lancet, 375(9721), 1657–1668. DOI ↗ |
| 别名 | RoB 2.0, RoB 2 | CONSORT, CONSORT 2010 |
| 相关 | 4 | 4 |
| 摘要≠ | RoB 2 is the Cochrane Collaboration's updated methodology for assessing the risk of bias in randomized controlled trials (RCTs). Published in 2019, it replaced the original Cochrane RoB tool with a more structured, transparent approach using signalling questions and domain-based judgments to evaluate five critical sources of bias. | The CONSORT (Consolidated Standards of Reporting Trials) Statement is a 25-item evidence-based checklist and flow diagram developed to standardize reporting of parallel-group randomized controlled trials. First published in 1996 and updated in 2010 (CONSORT 2010), it is endorsed by over 600 journals including The Lancet, JAMA, and BMJ, and is mandatory or strongly recommended for RCT manuscript submission across clinical research. |
| ScholarGate数据集 ↗ |
|
|